Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Operations: 2011-2025

Historic Cash from Operations for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $3.7 million.

  • Niagen Bioscience's Cash from Operations rose 5.64% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 412.77%. This contributed to the annual value of $12.1 million for FY2024, which is 70.14% up from last year.
  • Per Niagen Bioscience's latest filing, its Cash from Operations stood at $3.7 million for Q3 2025, which was up 199.43% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Cash from Operations ranged from a high of $8.6 million in Q4 2024 and a low of -$7.9 million during Q2 2021.
  • Its 3-year average for Cash from Operations is $2.9 million, with a median of $2.8 million in 2023.
  • Per our database at Business Quant, Niagen Bioscience's Cash from Operations crashed by 22,572.73% in 2021 and then soared by 2,577.97% in 2025.
  • Over the past 5 years, Niagen Bioscience's Cash from Operations (Quarterly) stood at -$4.9 million in 2021, then surged by 93.37% to -$328,000 in 2022, then skyrocketed by 297.87% to $649,000 in 2023, then surged by 1,222.50% to $8.6 million in 2024, then rose by 5.64% to $3.7 million in 2025.
  • Its Cash from Operations stands at $3.7 million for Q3 2025, versus $1.2 million for Q2 2025 and $7.9 million for Q1 2025.